New paradigm for stage III melanoma: from surgery to adjuvant treatment
Abstract Background Recently the 8th version of the American Joint Committee on Cancer (AJCC) classification has been introduced, and has attempted to define a more accurate and precise definition of prognosis in line with the major progresses in understanding the biology and pathogenesis of melanom...
| Main Authors: | , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2019-08-01
|
| Series: | Journal of Translational Medicine |
| Subjects: | |
| Online Access: | http://link.springer.com/article/10.1186/s12967-019-2012-2 |
| _version_ | 1819278427433205760 |
|---|---|
| author | Paolo Antonio Ascierto Lorenzo Borgognoni Gerardo Botti Michele Guida Paolo Marchetti Simone Mocellin Paolo Muto Giuseppe Palmieri Roberto Patuzzo Pietro Quaglino Ignazio Stanganelli Corrado Caracò |
| author_facet | Paolo Antonio Ascierto Lorenzo Borgognoni Gerardo Botti Michele Guida Paolo Marchetti Simone Mocellin Paolo Muto Giuseppe Palmieri Roberto Patuzzo Pietro Quaglino Ignazio Stanganelli Corrado Caracò |
| author_sort | Paolo Antonio Ascierto |
| collection | DOAJ |
| description | Abstract Background Recently the 8th version of the American Joint Committee on Cancer (AJCC) classification has been introduced, and has attempted to define a more accurate and precise definition of prognosis in line with the major progresses in understanding the biology and pathogenesis of melanoma. This new staging system introduces major changes in the stage III staging system. Indeed, surgical practice is changing in stage III patients, since, according to recent evidence, there is no survival benefit in radical lymph node dissection following a positive sentinel lymph node dissection. Therefore, some patients currently staged IIIB-C after dissection could be downgraded to IIIA (as in the case of patients with metastatic non-sentinel lymph nodes) since many completion lymph node dissections will no longer be performed. Moreover, new and effective targeted and immune strategies are being introduced in the pharmacological armamentarium in the adjuvant setting, showing major efficacy. Conclusions This article provides the authors’ personal view on the above-mentioned topics. |
| first_indexed | 2024-12-24T00:11:50Z |
| format | Article |
| id | doaj.art-d67769572e8547599de392a2adb4b9fe |
| institution | Directory Open Access Journal |
| issn | 1479-5876 |
| language | English |
| last_indexed | 2024-12-24T00:11:50Z |
| publishDate | 2019-08-01 |
| publisher | BMC |
| record_format | Article |
| series | Journal of Translational Medicine |
| spelling | doaj.art-d67769572e8547599de392a2adb4b9fe2022-12-21T17:24:51ZengBMCJournal of Translational Medicine1479-58762019-08-011711810.1186/s12967-019-2012-2New paradigm for stage III melanoma: from surgery to adjuvant treatmentPaolo Antonio Ascierto0Lorenzo Borgognoni1Gerardo Botti2Michele Guida3Paolo Marchetti4Simone Mocellin5Paolo Muto6Giuseppe Palmieri7Roberto Patuzzo8Pietro Quaglino9Ignazio Stanganelli10Corrado Caracò11Unit Melanoma, Cancer Immunotherapy and Innovative Therapies, Istituto Nazionale Tumori IRCCS Fondazione “G. Pascale”Ospedale Santa Maria Annunziata and University of FlorenceIstituto Nazionale Tumori IRCCS Fondazione “G. Pascale”Unit Melanoma and Rare Tumors, IRCCS Istituto Tumori Giovanni Paolo IIOncologia Medica B Policlinico Umberto I di RomaSurgical Oncology Unit, IOV-IRCCS of Padova and Dept. Surgery Oncology Gastroenterology, University of PadovaIstituto Nazionale Tumori IRCCS Fondazione “G. Pascale”Unit of Cancer Genetics, ICB-CNRIRCCS Fondazione Istituto Nazionale dei Tumori di MilanoDermatologic Clinic, Department of Medical Sciences, University of Turin Medical SchoolSkin Cancer Unit, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST), IRCCSIstituto Nazionale Tumori IRCCS Fondazione “G. Pascale”Abstract Background Recently the 8th version of the American Joint Committee on Cancer (AJCC) classification has been introduced, and has attempted to define a more accurate and precise definition of prognosis in line with the major progresses in understanding the biology and pathogenesis of melanoma. This new staging system introduces major changes in the stage III staging system. Indeed, surgical practice is changing in stage III patients, since, according to recent evidence, there is no survival benefit in radical lymph node dissection following a positive sentinel lymph node dissection. Therefore, some patients currently staged IIIB-C after dissection could be downgraded to IIIA (as in the case of patients with metastatic non-sentinel lymph nodes) since many completion lymph node dissections will no longer be performed. Moreover, new and effective targeted and immune strategies are being introduced in the pharmacological armamentarium in the adjuvant setting, showing major efficacy. Conclusions This article provides the authors’ personal view on the above-mentioned topics.http://link.springer.com/article/10.1186/s12967-019-2012-2StagingSurgeryAdjuvant treatmentMelanomaLymph node dissection |
| spellingShingle | Paolo Antonio Ascierto Lorenzo Borgognoni Gerardo Botti Michele Guida Paolo Marchetti Simone Mocellin Paolo Muto Giuseppe Palmieri Roberto Patuzzo Pietro Quaglino Ignazio Stanganelli Corrado Caracò New paradigm for stage III melanoma: from surgery to adjuvant treatment Journal of Translational Medicine Staging Surgery Adjuvant treatment Melanoma Lymph node dissection |
| title | New paradigm for stage III melanoma: from surgery to adjuvant treatment |
| title_full | New paradigm for stage III melanoma: from surgery to adjuvant treatment |
| title_fullStr | New paradigm for stage III melanoma: from surgery to adjuvant treatment |
| title_full_unstemmed | New paradigm for stage III melanoma: from surgery to adjuvant treatment |
| title_short | New paradigm for stage III melanoma: from surgery to adjuvant treatment |
| title_sort | new paradigm for stage iii melanoma from surgery to adjuvant treatment |
| topic | Staging Surgery Adjuvant treatment Melanoma Lymph node dissection |
| url | http://link.springer.com/article/10.1186/s12967-019-2012-2 |
| work_keys_str_mv | AT paoloantonioascierto newparadigmforstageiiimelanomafromsurgerytoadjuvanttreatment AT lorenzoborgognoni newparadigmforstageiiimelanomafromsurgerytoadjuvanttreatment AT gerardobotti newparadigmforstageiiimelanomafromsurgerytoadjuvanttreatment AT micheleguida newparadigmforstageiiimelanomafromsurgerytoadjuvanttreatment AT paolomarchetti newparadigmforstageiiimelanomafromsurgerytoadjuvanttreatment AT simonemocellin newparadigmforstageiiimelanomafromsurgerytoadjuvanttreatment AT paolomuto newparadigmforstageiiimelanomafromsurgerytoadjuvanttreatment AT giuseppepalmieri newparadigmforstageiiimelanomafromsurgerytoadjuvanttreatment AT robertopatuzzo newparadigmforstageiiimelanomafromsurgerytoadjuvanttreatment AT pietroquaglino newparadigmforstageiiimelanomafromsurgerytoadjuvanttreatment AT ignaziostanganelli newparadigmforstageiiimelanomafromsurgerytoadjuvanttreatment AT corradocaraco newparadigmforstageiiimelanomafromsurgerytoadjuvanttreatment |